A reappraisal of the mucoactive activity and clinical efficacy of bromhexineReportar como inadecuado

A reappraisal of the mucoactive activity and clinical efficacy of bromhexine - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Multidisciplinary Respiratory Medicine

, 12:7

First Online: 20 March 2017Received: 01 December 2016Accepted: 28 February 2017DOI: 10.1186-s40248-017-0088-1

Cite this article as: Zanasi, A., Mazzolini, M. & Kantar, A. Multidiscip Respir Med 2017 12: 7. doi:10.1186-s40248-017-0088-1


Since its introduction to the market in 1963, bromhexine, an over-the-counter drug, has been investigated for its activity in animal models and in humans with diverse respiratory conditions. Bromhexine is a derivate of the Adhatoda vasica plant used in some countries for the treatment of various respiratory diseases. Bromhexine has been found to enhance the secretion of various mucus components by modifying the physicochemical characteristics of mucus. These changes, in turn, increase mucociliary clearance and reduce cough. Principal clinical research studies were primarily developed in an era when stringent methodological approaches and good clinical practices were not developed yet. Clinical studies were conducted mainly in patients with chronic bronchitis and in patients with various respiratory diseases, and demonstrated the efficacy of bromhexine in improving respiratory symptoms. Furthermore, the co-administration of antibiotics with bromhexine amplified the actions of the antibiotic. Although the clinical evidence shows only modest but positive results, bromhexine is indicated for its mucoactive activity. Larger trials with adequate methodology are required to identify when treatment with bromhexine can improve clinical outcomes.

KeywordsBromhexine Cough Expectorants Pharmacological Action Bronchitis Chronic Pediatrics AbbreviationsBHCBromhexine

FEV1Forced expiratory volume in one second

FRCFunctional residual capacity

FVCForced vital capacity


LRTIsLower respiratory tract infections



PEFRPeak expiratory flow rate

PRACPharmacovigilance Risk Assessment Committe

RCPRaised cosine pulse

RCTRandomized controlled trial

RVResidual volume

TIDThree times a day

VASVisual analog scale

VCVital capacity

Download fulltext PDF

Autor: Alessandro Zanasi - Massimiliano Mazzolini - Ahmad Kantar

Fuente: https://link.springer.com/

Documentos relacionados